We have examined the pattern of striatal messenger RNA expression of over 8000 genes in a rat model of levodopa (l-DOPA)-induced dyskinesia and Parkinson disease (PD). 6-Hydroxydopamine (6-OHDA)-lesioned rats were treated with l-DOPA or physiological saline for 22 days and repeatedly tested for antiakinetic response to l-DOPA and the development of abnormal involuntary movements (AIMs). In a comparison of rats that developed a dyskinetic motor response to rats that did not, we found striking differences in gene expression patterns. In rats that developed dyskinesia, GABA neurons had an increased transcriptional activity, and genes involved in Ca 2+ homeostasis, in Ca 2+ -dependent signaling, and in structural and synaptic plasticity were upregulated. The gene expression patterns implied that the dyskinetic striatum had increased transcriptional, as well as synaptic activity, and decreased capacity for energy production. Some basic maintenance chores such as ribosome protein biosynthesis were downregulated, possibly a response to expended of ATP levels. D 2004 Elsevier Inc. All rights reserved.
Introduction
Parkinson disease (PD) is a progressive neurological disorder characterized by a degeneration of dopamine (DA) neurons in the substantia nigra (Dauer and Przedborski, 2003) . DA deficiency in areas innervated by nigral efferent neurons causes the motor symptoms of PD, that is, bradykinesia, rigidity, tremor, and postural instability (Gelb et al., 1999) . The etiology of the disease is largely unknown. l-Dihydroxyphenylalanine (levodopa, l-DOPA) is used to treat the symptoms of PD, but it leads to the development of abnormal involuntary movements (AIMs; dyskinesia) complicating long-term treatment (Bezard et al., 2001; Nutt, 2001; Rascol et al., 2003) .
We have developed a model of l-DOPA-induced dyskinesia in the rat (Cenci et al., 1998; Lee et al., 2000; Lundblad et al., 2002; Winkler et al., 2002) . Rats are lesioned unilaterally with 6-hydroxydopamine (6-OHDA) and subsequently treated with relatively low doses of l-DOPA for a few weeks, during which a majority of the animals develop abnormal involuntary movements (AIMs), while some rats are resistant. This model allows us to study the biochemical and molecular factors involved in dyskinesia in a pharmacologically and genetically controlled environment.
One of the main target areas of nigral DA neurons is the striatum, a structure critically involved in the pathophysiology of parkinsonian motor symptoms (Sian et al., 1999) . The striatum is also a prominent site of maladaptive molecular and synaptic plasticity in l-DOPA-induced dyskinesia (Andersson et al., 1999 (Andersson et al., , 2001 Cenci et al., 1998; Johansson et al., 2001; Picconi et al., 2003; Westin et al., 2001) . Most of the neurons in the striatum are projection neurons that use GABA as their neurotransmitter. These neurons can be further classified based on their expression of dopamine receptor subtypes and the neuropeptides enkephalin, dynorphin, and substance P (Gerfen, 1992a,b; Le Moine et al., 1991) . The striatum has, in addition, interneurons expressing either acetylcholine, parvalbumin, or somatostatin (Kubota and Kawaguchi, 2000; Parent and Hazrati, 1995) .
The aim of this study was to define changes in striatal gene expression that are associated with l-DOPA-induced dyskinesia in the rat model. Gene array technology was used to study the expression of over 8000 genes and expressed sequence tags (ESTs) in the striatum. Approximately 3000 of the genes examined were of known or inferred function and were expressed above back- 
